{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-040697","form_type":"8-K","ticker":null,"cik":"0001827506","company_name":"Tourmaline Bio, Inc.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.860686+00:00","generated_at":"2026-06-19T09:43:36.910444+00:00","sec_items":["2.02","2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Talaris discontinues kidney transplant trials, cuts 1/3 of staff, explores strategic alternatives","bullets":["Discontinues FREEDOM-1 and FREEDOM-2 kidney transplant trials due to slow enrollment; continues FREEDOM-3 scleroderma trial.","Workforce reduced by ~1/3; remaining employees focus on cell therapy CMC and FREEDOM-3 trial.","Expects ~$2.9M in restructuring costs in Q1-Q2 2023; cash position ~$181.3M as of Dec 31, 2022.","Initiates comprehensive strategic review including possible business combinations or divestiture of cell therapy CMC.","No timetable set for strategic review; suspends further program guidance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-040697","json":"https://secwatch.observer/filing/0001193125-23-040697.json","markdown":"https://secwatch.observer/filing/0001193125-23-040697.md","text":"https://secwatch.observer/filing/0001193125-23-040697.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827506/000119312523040697/0001193125-23-040697-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827506/000119312523040697/d357370d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:43:36.910444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5608916df8a2670e1840aec5768717d54a331bde","claim":"Tourmaline Bio, Inc. announced a restructuring with charges of approximately $2.9 million for retention, severance and other employee termination-related costs affecting workforce reduction by approximately one-third (reducing the Company's workforce by approximately one-third).","evidence_excerpt":"clinical development programs and further prioritization of the Company’s resources as it assesses strategic alternatives. The Company estimates that it will incur approximately $2.9 million for retention, severance and other employee termination-related costs in the first and second quarters of 2023. The estimate of costs that the Company expects to incur and the","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827506/000119312523040697/0001193125-23-040697-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2.9 million for retention, severance and other employee termination-related costs"},{"label":"Affected area","value":"workforce reduction by approximately one-third"},{"label":"Headcount","value":"reducing the Company's workforce by approximately one-third"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}